The tumor suppressor gene p53 is a transcription factor that mediates both cell cycle arrest and apoptosis. Interestingly, p53 also induces differentiation of a number of tissues, including leukemic cells. However, although p53-mediated differentiation of leukemic U-937 cells depends on the transcriptional activity of p53, a p53 target gene mediating differentiation has hitherto not been identified. To screen for novel p53 target genes in leukemic cells, a cDNA microarray analysis was performed with U-937-4/ptsp53 cells, expressing a temperature-sensitive p53 mutant. We report that transcription of the Staf50 (stimulated transacting factor of 50 kDa) gene is upregulated in response to wild-type p53 in U-937-4, K562 and MCF-7 cells. Staf50 was directly activated by p53, as determined by the independence of de novo protein synthesis. Moreover, while the proximal promoter of Staf50 was found not to be p53 responsive, a functional enhancer-like p53-response element in intron 1 of the Staf50 gene was identified that was also transactivated by the p53-family member p73. Direct binding of p53 to the response element was shown by electrophoretic mobility shift analysis. Ectopic expression of Staf50 in U-937 cells resulted in reduced clonogenic growth. Moreover, levels of endogenous Staf50 mRNA correlated to all-trans retinoic acid-induced differentiation of promyelocytic NB-4 and HL60 cells, suggesting that Staf50 could be involved in proliferation and/or differentiation of leukemic cells.
Introduction
One of the key proteins protecting tissues from malignant transformation is the tumor suppressor protein p53 (Levine, 1997) . The tumor suppressing activity of p53 is usually explained by its ability to prevent the expansion of potentially malignant cells, either by the induction of apoptosis or by arrest of the cell cycle (Ko and Prives, 1996; Hansen and Oren, 1997; Levine, 1997) . The major mechanism by which p53 induces biological effects is by transcriptional transactivation of specific target genes. Transactivation involves binding to p53-response elements in the target genes. A consensus sequence for p53 binding has been identified and shows an internal symmetry consisting of two copies of the 10 base pair (bp) motif 5 0 -PuPuPuC(A/ T)(T/A)GPyPyPy-3 0 separated by 0-13 bp . Only one of the two copies is insufficient for binding. Several point mutations of p53 present in malignant cells impair or abolish the binding of the p53 consensus binding site . Among the p53 target genes identified, p21 /WAF1 is considered to be one of the most important because its products are essential for p53-mediated cell cycle arrest (El-Deiry et al., 1993) . Bax and Noxa are examples of p53 target genes, the products of which are involved in the regulation of cytochrome release from mitochondria that contribute to apoptosis (Miyashita et al., 1994; Oda et al., 2000) . However, given that the number of potential p53-binding sites in the human genome has been estimated to 200-300 (Tokino et al., 1994) , several p53 target genes most probably remain unidentified. Furthermore, some p53 target genes may respond in a tissue-specific manner (Fei et al., 2002) .
Interestingly, p53 has been shown to have a role in the differentiation process of a number of different tissues including pancreatic carcinoma cells, muscle cells, keratinocytes, neurons, thyroid cells (Soddu et al., 1996; Almog and Rotter, 1997; Lang et al., 1998) and various hematopoietic cell lines (Shaulsky et al., 1991; Feinstein et al., 1992; Banerjee et al., 1995; Ehinger et al., 1995 Ehinger et al., , 1996 Rizzo et al., 1998) . However, the molecular mechanisms behind p53-mediated differentiation are poorly understood. Although the expression of the wellknown p53 target gene p21 /WAF1 correlates to the induction of differentiation in some leukemic cell lines (Liu et al., 1996; Asada et al., 1998; Wang et al., 1998) , p21 /WAF1 expression is not sufficient for differentiation of K562 cells and U-937 cells (Chylicki et al., 2000a; Ellisen et al., 2001) . Differentiation of U-937-4 cells mediated by ectopically expressed p53 is, however, dependent on the transcriptional activity of p53 (Chylicki et al., 2000b) , but no p53 target gene mediating p53-induced differentiation has hitherto been identified.
The aim of this work was to identify novel p53 target genes in myeloid cells. Using cDNA microarray as a screening for candidate genes, we identified the gene coding for Staf50 (stimulated transacting factor of 50 kDa) as a p53-responsive gene. The Staf50 gene, located on chromosome 11p15, encodes a member of the ring-finger family of proteins involved in gene regulation, ubiquitination, DNA recombination and DNA repair (Tissot and Mechti, 1995; Tissot et al., 1996; Joazeiro and Weissmann, 2000; Reymond et al., 2001) . The expression of Staf50 is induced by interferons a/b and g in some tissues (Tissot and Mechti, 1995) , while strongly repressed during T-cell activation (Gongora et al., 2000) , suggesting antiproliferative effects. Here, we report that transcription of Staf50 is directly activated by ectopically expressed p53 in myeloid cells. We also show that induction of differentiation of NB4 and HL60 cells in vitro correlates to the expression of Staf50, and that overexpression of Staf50 reduces clonogenic growth of U-937cells.
Results

Identification of Staf50 as a p53 target gene
U-937-4/ptsp53/A2 cells express the temperature-inducible p53 mutant ptsp53 (Ehinger et al., 1996) . Upon incubation at the permissive temperature (321C), U-937-4/ptsp53/A2 cells show signs of differentiation, reflecting the differentiation inducing capacity of wild-type p53 (Ehinger et al., 1996) . To identify novel target genes of p53, a cDNA microarray was performed. U-937-4 control cells and U-937-4/ptsp53/A2 cells were incubated at 37 and 321C for 4 h, after which RNA was prepared and microarray analysis was performed. The analysis of both control cells and U-937-4/ptsp53/A2 cells at 37 and 321C made it possible to exclude genes affected by the temperature shift only. Some previously identified p53 target genes were indicated to be p53 responding in the array analysis. These were APO-1, Mdm2 and the TRAIL receptor (Momand and Zambetti, 1997; Wu et al., 1999; Munsch et al., 2000) . In addition, the Staf50 gene, not previously reported to be regulated by p53, was up regulated threefold in response to p53 activation at the permissive temperature, suggesting that Staf50 is a novel p53 target gene.
To verify Staf50 as a p53-regulated gene, a Northern blot analysis was performed. U-937-4 control cells and U-937-4/ptsp53/A2 cells were incubated at the permissive temperature (321C). After 0, 4, 8, 12, 24, 48 and 72 h, RNA was extracted and Staf50 expression was analysed. As shown in Figure 1a , the expression of Staf50 in control U-937-4 cells was below the detection limit. However, in p53-expressing U-937-4/ptsp53/A2 cells, Staf50 expression was evident after 4 h at 321C (Figure 1a) . Neither U-937-4/ptsp53/A2 cells nor U937-4 control cells showed any detectable expression of Staf50 at the nonpermissive temperature (371C) (data not shown). The response of Staf50 expression to p53 induction was rapid and comparable to that of the wellknown p53-regulated gene p21 /WAF1
, supporting that Staf50 might be a direct p53 target gene (Figure 1a ). The expression of Staf50 peaked at 24 h, to thereafter decline, consistent with a negative feedback mechanism, such as mdm2-induced degradation of p53 (Lohrum and Vousden, 2000) . To further characterize the p53-activated induction of Staf50-mRNA, actinomycin D or cycloheximide (CHX) was added to cells immediately prior to the shift to permissive temperature. As shown in Figure 1b , Staf50 expression was dependent on de novo mRNA synthesis, since it was blocked by the presence of actinomycin D, but independent of de novo protein synthesis since it was unaffected, or even increased, by the addition of CHX. In parallel control experiments, CHX was shown to reduce overall protein synthesis by 490% (data not shown). Taken together, the results confirm that Staf50 mRNA expression is directly activated by p53 in U-937-4 cells, and thus that Staf50 is a direct target gene of p53.
p53-related induction of Staf50 mRNA in leukemic K562 and breast carcinoma MCF-7 cells
To demonstrate that p53-induced expression of Staf50 is not restricted to U-937-4 cells, Staf50 expression in response to p53 in leukemic K562 cells was investigated by RT-PCR. To this end, K562 cells expressing the temperature-inducible mutant form of p53 were utilized (Chylicki et al., 2000a) . Consistent with the results 4, 8, 12, 24, 48 and 72 h, total RNA was extracted and subjected to Northern blot analysis. GAPDH was used as a control for equal loading and p21 /WAF1 as a reference for the transcriptional activity of p53. (b) Induction of Staf50 mRNA in response to wild-type p53 in the absence of translation of new proteins and RNA synthesis. U-937-4/ptsp53/A2 cells were incubated with or without 1 mg/ml actinomycin D or 100 mg/ml CHX at 321C. After 0, 6 and 12 h, total RNA was isolated and subjected to Northern blot. GAPDH was used as a control for equal loading (Gongora et al., 2000) .
UV-irradiation has been shown to induce wild-type p53 activity in the breast cancer cell line MCF-7, leading to the induction of p53 target genes (Sharma and Srikant, 1998; Wang et al., 1999; Swiatecka et al., 2000) To determine whether Staf50 is induced in MCF-7 cells in response to UV radiation, MCF-7 cells were exposed to 999 mJ UV in UV cross-linker (GS Gene Linker s UV chamber, BioRad) and incubated for 0, 8, 12 and 24 h, after which RT-PCR analysis was performed. An induction in p53 activity was corroborated by a decrease in p21 /WAF1 expression (Figure 2b ), a previously reported response to wild-type p53 activity in MCF-7 cells (Wang et al., 1999) . The expression of Staf50 was apparent 8 h after UV-irradiation, suggesting that the expression of Staf50 was provoked by endogenously expressed p53 in MCF-7 cells (Figure 2b ).
Staf50 expression is induced by interferon-a
Staf50 is an interferon-inducible gene in the lymphoblastoid Daudi cell line (Tissot and Mechti, 1995) . U-937-4 control cells were incubated with 5000 U/ml interferon-a at 371C. After 0, 8 and 12 h, RNA was extracted and subjected to Northern blot analysis. As shown in Figure 3 , interferon-a provoked the expression of Staf50, verifying that Staf50 expression is also interferon-a inducible in U-937-4 cells. Moreover, since U-937-4 cells lack endogenous p53, Staf50 expression can also be induced by p53-independent pathways in these cells.
Cloning of the Staf50 promoter
Our results above, indicating that Staf50 is a direct target gene of p53, prompted us to characterize the Staf50 promoter. To identify the transcription start, total RNA extracted from the leukemic cell lines, U-937-4/ptsp53/A2 or K562/ptsp53/A2 incubated at 321C for 6 h, was subjected to 5 0 -RACE as described in the Materials and methods. Repeated RACE experiments were performed, each resulting in PCR products of approximately 190 bp. After cloning into the pCR-4-TOPO plasmid, 12 individual clones were sequenced and all the sequences were found to be identical. The sequence was aligned to Staf50 cDNA and found to match completely the previously reported sequence upstream of the translation start (Tissot and Mechti, 1995) , and contained additional 137 bp (Figure 4) . These results indicate the initiation of transcription at À245 bp upstream of the translation start ATG codon. From the obtained cDNA sequence, oligonucleotide primers were synthesized and genomic DNA upstream of the transcription start was cloned by PCR, using the Genome Walk kit, as described in the Materials and methods. The largest PCR product obtained was approximately 500 bp, and sequencing revealed complete identity to the genomic sequence obtainable from GeneBank (Accession #AC026090). However, when matching the 394 bp 0 -RACE technique. The cell lines U-937-4/ ptsp53/A2 and K562/ptsp53/A2 were incubated for 6 h at 321C after which RNA was isolated. RACE resulted in PCR products ending on À245 bp. Numbering starts from the first nucleotide upstream of the translation start codon ATG. The solid line indicates previously published cDNA sequence (Tissot and Mechti, 1995) Staf50 as a novel p53 target gene S Obad et al promoter sequence (Figure 5a ) to the transcription factor database TRANSFAC with the MOTIF search program (http://motif.genome.ad.jp/), no putative p53-response elements were identified.
Cloning of intron 1 of the Staf50 gene and identification of a potential p53-binding motif
Computer analysis of the proximal promoter of Staf50 did not reveal any potential p53-binding motifs and therefore our attention was focused upon intron 1. Indeed, a computer-based search in the sequence of intron 1 (Gene Bank Accession #AC026090) revealed a p53 consensus binding site 827-846 bp downstream of the transcription start ( Figure 5 ). This prompted us to clone this region of intron 1 to further investigate the significance of the p53-binding motif. Thus, 1359 bp of intron 1 was amplified by PCR and cloned into pGL3 for further analysis in transient reporter gene transfections as described in the Materials and methods.
p53-response element is functionally active in U-937-4 cells
To characterize functionally the potential p53 response element identified in intron 1 of the Staf50 gene, luciferase-reporter transfections were performed. We initially chose to investigate its effect on SV40-driven expression of the luciferase gene, and therefore cloned the intron 1 sequence downstream of the luciferasereporter gene in the pGL3 promoter vector ( Figure 6 ). Indeed, the intron 1 sequence conferred an eightfold enhancement of SV40-driven luciferase expression ( Figure 6 ). Moreover, the enhancement was dependent on p53, since it was present in U-937-4/ptsp53/A2 cells, but not in U-937-4 control cells, incubated at the p53-permissive temperature. Mutagenesis of the identified p53-response element (Figure 5b ), eliminated the p53 response, demonstrating its functional significance ( Figure 6 ). The transcriptional activity of the SV40-promoter alone was decreased in the presence of active p53 (see legend of Figure 6 ), confirming earlier reports (Jackson et al., 1993) . Altogether, these results indicate that the p53-response element is functional and mediates p53-induced transcriptional activation.
p53-response element is functionally active in conjunction with the proximal promoter of Staf50
The results above demonstrate that the p53-response element in intron 1 can confer p53 responsiveness to the viral SV40 promoter. To investigate its function in conjunction with the proximal Staf50 promoter, the promoter region was cloned into a pGL3 basic vector containing the intron 1 sequence downstream of the luciferase gene (Figure 7 ). When transfected into U-937-4/ptsp53/A2 cells at the permissive temperature, the p53-response element conferred a sevenfold enhancement of transcription from the proximal Staf50 promoter (Figure 7) , consistent with the results obtained with SV40 promoter (Figure 6 ). Specific mutation of the p53-response element eliminated the p53-dependent enhancement of transcription. Interestingly, the intron 1 sequence, to some extent, also enhanced transcriptional activity of the Staf50 promoter in U-937-4 control cells, lacking p53 (Figure 7 ). The reason for this is unclear, but seems to be unrelated to p53 in as much as it was only partially affected by site-directed mutagenesis of the p53 response element (Figure 7 ). Similar to the observations for the SV40 promoter, the transcriptional activity of the Staf50-promoter alone was suppressed in U-937-4/ptsp53/A2 cells, as compared to U-937-4 control cells (see legend of Figure 7 ). These results are p53 binds to the p53-response element in intron 1 of the Staf50 gene
To verify that p53 directly binds to the identified p53-response element of intron 1, we conducted gel shift assays using oligonucleotide probes corresponding to the p53-response element ( Figure 5 ). As shown in Figure 8 , the p53 protein bound to the oligonucleotide (lane 2), as indicated by a mobility shift. The shift was not apparent with labeled mutant oligonucleotide probe (lane 3). Furthermore, competitive binding with a 100-or 500-fold excess of unlabeled oligonucleotide (lane 4 and 5), but not with an excess of mutated cold oligonucleotide (lane 6 and 7), indicated specificity of the binding. Free radioactive oligonucleotide was measured by densitometry in order to verify that the radioactivity was equally loaded in each lane (data not shown). These results indicate that p53 has the potential to bind directly to the p53-response element in intron 1 of the Staf50 gene. The antibody to p53 (pAb421), added to stabilize DNA binding of p53 (Takenaka et al., 1995) , did not result in any mobility shift in the absence of recombinant p53 protein (lane 8). (Liu et al., 2000) . No increase in response to vitamin D3 was noticed ( Figure 9 and data not shown). Differentiation induction of NB4 and HL60 cells was confirmed by FACS analysis 3 days after the addition of ATRA or vitamin D3. As expected, a strong increase in the expression of CD11c (NB4) and CD11b (HL60) was observed (data not shown).
p53-responsive element is transactivated by p73
The results above clearly demonstrate that p53 directly transactivates gene expression of Staf50. However, since most leukemic cell lines, including HL60 and NB4 cells, lack functional endogenous wild-type p53 (Wolf and Rotter, 1985; Sugimoto et al., 1992; Rizzo et al., 1998; Song et al, 1999) , an alternative mechanism must be responsible for the observed increase of Staf50 expression during ATRA-induced differentiation of these cells. The p53-family member p73 is expressed in some leukemic cells including HL60 and NB4 (Peters et al., 1999; Tschan et al., 2000) . Given that p73 can induce cell cycle arrest and transactivation of many p53 target genes, (Yang and McKeon, 2000) , we asked whether p73 can induce transcription also from the p53-response element in the Staf50 gene. Therefore, wild-type p73 was transiently transfected to U-937-4 cells together with the luciferase reporter used above, containing the Staf50-promoter and the p53-response element. As shown in Figure 10 , p73 indeed conferred transcription of the reporter. Moreover, the effect of p73 was dependent on the p53-response element, as judged by its sensitivity to mutation (Figure 10 ), altogether suggesting that p73 can mediate direct transcriptional regulation of Staf50. Next, we analysed the expression of p73 in HL60 and NB4 cells using RT-PCR. Indeed, p73 was expressed, although we were not able to demonstrate an increase in the levels of p73 during ATRA or vitD3-induced differentiation of NB4 or HL60 cells (data not shown). These results are consistent with previously published data showing early increase in levels of p73 in response to DMSO, but not to ATRA (Tschan et al., 2000) . We conclude that p73 is potentially involved in the regulation of Staf50 expression during differentiation.
Overexpression of Staf50 in U-937 cells confers reduced clonogenic growth in soft agar
To reveal the functional significance of Staf50, we performed experiments in which Staf50 was overexpressed in U-937 cells followed by culture in soft agar. U-937 cells were chosen since the transduction efficiency by electroporation is much higher than that obtained with NB4 or HL60 cells. An expression vector encoding Staf50 was transfected to cells together with an expression vector for green flourescent protein (GFP). The cdk inhibitor p21 /WAF1 and pcDNA3 were used as positive and negative controls, respectively. After 24 h, GFP-positive cells were sorted and seeded in soft agar. Colonies were scored after 9 days. As shown in Table 1 . These results indicate that Staf50 can confer antiproliferative effects, consistent with a possible role of Staf50 in growth regulation during terminal differentiation.
Discussion
The tumor suppressor p53 is implicated in the differentiation program of a number of different tissues including leukemic cells (Feinstein et al., 1992; Banerjee et al., 1995; Soddu et al., 1996; Almog and Rotter, 1997; Lang et al., 1998) . The mechanisms for p53-mediated differentiation are unclear, but p53-mediated differentiation of leukemic U-937-4 cells is dependent on the transcriptional activity of p53 (Chylicki et al., 2000b) . Transcriptionally regulated target genes are therefore expected to be critical for p53-mediated enhancement of differentiation. An obvious candidate is the inhibitor of cyclin-dependent kinases p21 /WAF1
, which can induce cell cycle arrest and is involved in some differentiation programs (Asada et al., 1998; Casini and Pelicci, 1999; Zhang et al., 1999) . However, p21 /WAF1 alone does not seem to mediate the p53-induced differentiation of K562 cells, and neither does the p53-mediated differentiation of K562 cells seem to rely on a cell cycle arrest mediated by the hypophosphorylated form of the retinoblastoma Staf50 as a novel p53 target gene S Obad et al protein (Ehinger et al., 1997; Chylicki et al., 2000a) . Therefore, to gain a better understanding of the mechanisms for p53-mediated differentiation, it is of particular interest to identify novel p53 target genes in leukemic cells that can potentially mediate differentiation signals.
Here, we report that the Staf50 gene is directly activated by p53. This conclusion is based on our observations that expression of Staf50 mRNA was upregulated in response to wild-type p53 activity in leukemic cell lines. In addition, the induction of Staf50 was also evident in response to UV-irradiation in MCF-7 cells, indicating that Staf50 could also be induced in response to endogenously expressed p53. Induction of Staf50 was dependent on de novo mRNA synthesis, but was not dependent on de novo protein synthesis, consistent with a direct transcriptional activation. We provide a molecular mechanism for the observed response of Staf50 expression to p53 by the identification of a functional enhancer-like p53-response element located in intron 1 of the Staf50 gene. The sequence of the p53-response element almost completely matches (17 out of 20) the consensus binding site described by ElDeiry et al. (1992) . In particular, the tandem core sequence CATG completely adhered to the consensus CWWG ( Figure 5b ) and mutagenesis of this sequence abolished the p53 responsiveness. The proximal promoter of Staf50, on the other hand, was not transcriptionally activated by p53. Rather, p53 induced transcriptional repression on the Staf50-promoter alone. Interestingly, the location of p53-response elements in intron 1, and not in the proximal promoter upstream of the transcription start, is a common feature of some p53 target genes, such as GADD45, KILLER/DR5 and Mdm2 (Kastan et al., 1992; Zauberman et al., 1995; Takimoto and El-Deiry, 2000) . In agreement with previous reports, Staf50 expression was also inducible by IFN-a. Since this also occurred in the absence of p53, expression of Staf50 is not absolutely dependent on p53. Whether identical transcription start sites are utilized upon induction with IFN-a or p53 was not investigated. Very recently it was reported that interferon can increase the expression of p53, giving this tumor suppressor a role in signaling downstream of interferon (Pestka, 2003; Takaoka et al., 2003) . Together with our present results, indicating that expression of an interferon-inducible gene, Staf50, can be enhanced by p53, data thus suggest mutual positive crosstalk between the interferon and p53 signaling pathways.
What is the functional role of Staf50? Staf50 is expressed in Daudi and HeLa cells after treatment with IFN a/b or IFNg (Tissot and Mechti, 1995) , indicating a role in IFN-mediated antiviral action. Consistently, Staf50 suppressed the transcriptional activation from the LTR promoter of human immunodeficiency virus (HIV) type-I (Tissot and Mechti, 1995) and Staf50 is expressed in resting T-lymphocytes even in the absence of exogenous IFN treatment. However, it is strongly repressed upon activation of T-lymphocytes by anti-CD28 and anti-CD2mAb, suggesting a role in T-cell regulatory processes (Gongora et al., 2000) . The mouse Rpt-1 gene product, which shows a 44% homology with Staf50, is similarly expressed in resting T cells and downmodulates expression from the HIV-I promoter (Patarca et al., 1988) . These data indicate a role for Staf50 in antiviral response and that Staf50 expression is negatively correlated to cell proliferation, suggesting that Staf50 could be involved in cell cycle arrest. Our present finding that overexpression of Staf50 resulted in reduced clonogenic growth of leukemic U-937 cells supports this notion. Therefore, Staf50 may be a mediator of cell proliferation arrest in p53 and interferon signaling pathways.
By which molecular mechanisms does Staf50 exert its functions? Staf50 is a ring-finger protein belonging to a family of proteins containing a tripartite motif (TRIM), composed of zinc-binding domains, B-boxes and a coiled-coil region (Reymond et al., 2001) . Biological functions of TRIM proteins are largely unknown, but the TRIM family includes the promyelocytic leukemia (PML) protein. The function of PML is disturbed by the leukemic fusion protein PML/retinoic acid receptor a (PML/RARa), which is formed as a result of the t(15;17) translocation present in acute PML. PML functions as a tumor suppressor, controlling apoptosis, cell proliferation and senescence (reviewed in Salomoni and Pandolfi, 2002) . It is tempting to speculate that Staf50 could have similar functions, although the cytosolic localization of Staf50 (Reymond et al., 2001 ) is in contrast to the nuclear localization of PML. The common function of TRIM proteins may therefore be to serve to define functional subcompartments in the nucleus, as well as in the cytoplasm (Reymond et al., 2001) .
One objective of the present investigation was to reveal p53 target genes possibly involved in differentiation. Our findings that Staf50 is upregulated in response to differentiation induction of promyelocytic NB4 and HL60 cells with ATRA is therefore of great interest. One component of the differentiation program is cell cycle arrest, and Staf50 could have a role in cell cycle regulation during differentiation. Present data showing reduction in clonogenic growth as a result of overexpression in leukemic U-937 cells lends support to this hypothesis.
It is important to emphasize that the leukemic NB4 and HL60 cells lack endogenous expression of wild-type functional p53. Therefore, although p53 transactivates Staf50 in our engineered p53-transfected cell lines, p53 cannot be the mediator of Staf50 expression during ATRA-induced differentiation of wild-type cell lines. The absence of p53 in the wild-type cell lines therefore calls for an explanation for the observed upregulation of Staf50 during differentiation induction. The expression of the p53-family member p73 is enhanced during certain differentiation of leukemic cells (Tschan et al., 2000) . Therefore, p73 is a candidate for the regulation of Staf50 in ATRA-induced HL60 and NB4. The reporter experiments demonstrating that the p53-responsive element in the Staf50 gene indeed can be transactivated also by p73, lend support to the notion of p73-regulated transcriptional control of Staf50. Therefore, it is tempting to speculate that certain conditions for Yang et al., 2002) , changes in p73 activity might still occur. Therefore, p73 should be regarded as potentially involved in Staf50 expression during differentiation of leukemic cells.
In conclusion, we provide evidence for Staf50 as a novel direct transcriptional target gene of p53, mediated by a p53-response element located in intron 1 of the Staf50 gene, which also is a functional p73-response element. The expression of Staf50 positively correlates to certain differentiation-induction of leukemic cells. Furthermore, the conferred reduction of clonogenic growth of leukemic U-937 cells in response to overexpression of Staf50 suggests an antiproliferative role for Staf50 in myeloid cells.
Materials and methods
Cell culture
MCF-7 (ATCC#HTB-22), NB-4 (DSZ#ACC207), HL60 (ATCC#CCL-240) U-937-4 (Sundstro¨m and Nilsson, 1976; Olsson et al., 1983) , K562 (Lozzio and Lozzio, 1975) cells, and the U-937-4/ptsp53/A2 and K562/ptsp53/A2 cell lines, expressing the temperature-sensitive p53 mutant pLTRp53cGval135 (ptsp53) (Ehinger et al., 1996; Chylicki et al., 2000a) were cultured in RPMI-1640 supplemented with 10% FCS. For induction of p53 activity in U-937-4/ptsp53/A2 and K562/ ptsp53/A2 cell lines, cells were incubated at 321C.
cDNA microarray
Arrays were produced using approximately 4000 sequence verified human cDNA clones (Research Genetics, Invitrogen Corporation). Clones were PCR amplified, purified, dissolved in 50% DMSO and printed in duplicate on amino-silanecoated glass slides (Corning CMT-GAPS) using a MicroGrid2 robot (BioRobotics) equipped with MicroSpot2500 pins (BioRobotics). Total cellular RNA was extracted from U-937-4 control cells and from the temperature-sensitive clone ptsp53/A2 with RNeasy Mini Kit (Qiagen Gmbh, Hilden, Germany) according to the manufacturer's instructions and used for the production of fluorescence-labeled cDNA probe. Reverse transcription of total RNA was performed with poly(d)T primer, Superscript II enzyme (Clontech) and Cy3-dUPT or Cy5-dUTP, respectively (Amersham). Labeled cDNA was hybridized in 0.2% SDS and 3 Â SSC to the microarray slides under coverslips in a hybridization chamber over night at 651C. After washing with 0.5 Â SSC, 0.1% SDS for 4 min and repeated washes with 0.5 Â SSC, 0.001% SDS and 0.06 Â SSC also for 4 min the arrays were scanned in an Axon 4000A Microarray Scanner (Axon Instruments) and analysed with the software program GenePix Pro 3.1 software (Axon Instruments).
Northern blot analysis
Northern blot was performed with Express-Hybridization solution (Clontech, Palo Alto, USA) according to the manufacturer's instructions. Briefly, 15 mg total RNA was run on a denaturing agarose gel and transferred to nylon membrane. Staf50 cDNA (Research Genetics) was labeled with [a-32 P]dCTP and hybridization was performed at 681C. After high stringency wash, membranes were analysed using a Molecular Imaging FX analyzer (BioRad, Melville, NY, USA). 0 -CCA GCC AGG TCC AGA CGC AGG-3 0 . For semiquantitative analysis, PCR products were analysed after a distinct number of amplification cycles, as indicated. The amount of PCR product was determined by densitometry and normalized to the expression of actin.
RT-PCR
The 5 0 -end of the Staf50 mRNA was identified by 5 0 -RACE using the First choicet RLM-RACE kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The outer and nested primers were constructed based on the previously published Staf50 cDNA sequence (Tissot and Mechti, 1995) . The outer and nested primer for Staf50 cDNA were: 5 0 -TCC CTT GGC TTC CTT CTG TCT-3 0 and 5 0 -GAC TCC TCT AGA ACA AAC TCC TGC-3 0 , respectively. The PCR product was subcloned and 12 individual clones were sequenced.
Genomic cloning and mutagenesis
Cloning of the proximal promoter sequence upstream of the transcription start was performed by PCR utilizing the Human Genomewalkert-kit (Clontech), according to the recommendation's of the manufacturer. Based on the cDNA sequence, oligonucleotide primers annealing upstream of the transcription start were synthesized: 5 0 -TCC AAA GCA GAG GAG TCT TGA ATC-3 0 and the nested primer, 5 0 -GAC TCC AGA TCT AGA AGA GTG AAG GCA GGG CAC GAG-3 0 . In an analogous manner, a part of intron 1 of the Staf50 gene was PCR-amplified. Primers annealing to intron 1 were synthesized: outer and nested primers were 5 0 -CCT GTG GGG AAA CTC ATT TGT GG-3 0 and 5 0 -GAC TCC AGA TCT TGC CCT GCC TTC ACT CTT CTC CC-3 0 , respectively. After subcloning of promoter and intron sequences into the pGL3 basic vector and pGL3 promoter vector (Clonetech), sequencing was performed to verify the identity to previously reported genomic sequence (Gene Bank Accession #AC026090). For site-directed mutagenesis of the potential p53-response element, oligonucleotide primers including the desired mutations were synthesized and used in two-step splice overhang extension PCR as described (Gullberg et al., 1992) . After cloning into the pGL3-vector, sequencing was performed to verify the presence of the desired mutation.
Vectors
The pGL3/Waf1/Luc vector, carrying 2.3 kb of the p21 /WAF1
promoter sequence in front of a firefly luciferase-reporter gene was kindly provided by Dr Moshe Oren (Revhot, Israel). The expression vector for p73, p73aHA/pcDNA3 was a generous gift from Dr D Caput (Harvard, Boston) and the Staf50 cDNA in the pBluescript vector was a kind gift from Dr Nadir Mechti (Montpellier, France) and was cloned into the pCDNA3 vector with the restriction sites XbaI/XbaI. The p21 /WAF1 /pCDNA3 vector was made as described (Chylicki et al., 2000a) . The pEGFP-N1 vector was from Clonetech. Both the pGL3 promoter vector, with the SV40 promoter driving expression of luciferase, and the pGL3 Basic vector were from Promega.
Luciferase-reporter assays
Plasmid luciferase-reporter DNA (15 mg) was introduced into 8 Â 10 6 U-937-4 cells by electroporation using the BioRad gene-pulser (BioRad) with electrical settings of 280 V and 960 mF. After incubation at 321C for 16 h, the luminescence was determined using the Dual-Luciferase Reporter Assay System (Promega Corp.) according to the manufacturer's instructions and readings performed on a TD 20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). In experiments with p73, 15 mg plasmid luciferase-reporter DNA was cotransfected with 6 mg p73aHA/pCDNA3 or, as control, empty plasmid pCDNA3.
Electromobility shift assay (EMSA)
Baculovirus-derived recombinant p53 (wild type) was purchased from Oncogene (San Diego, CA, USA). The oligonucleotides (see below) were 5 0 -end labeled using PNK Kinase (Roche) and [g- 32 P] (Amersham, Sweden), purified on MicroSpint G-25 columns (Amersham Pharmacia Biotech), and thereafter annealed to the corresponding complementary oligonucleotide. Recombinant p53 protein (50 ng) was incubated for 20 min at RT with 3 pmol oligonucleotide (30 000 c.p.m.) in a binding buffer consisting of 50 mM TrisHCl, pH 7.5, 35 mM MgCl 2 , 40% glycerol, 50 mM DTT, 1 mg/ ml poly-dIdC, 1 mg/ml bovine serum albumin and 0.3 mg monoclonal p53 (AB-1) Ab (clone PAb421) (Oncogene). The antibody directed against the C-terminal of p53 stabilizes the binding of p53 to DNA (Takenaka et al., 1995) . Samples were separated on PAGE using a 6% polyacrylamide TBE gel (Invitrogen) and analysed with a Molecular Imaging FX analyzer (BioRad). Probes used for EMSA were: wild-type p53, 5 0 -ACT GTG ACA TGT CTA GGC ATG TAG CAA-3 0 and mutant p53, 5 0 -ACT GTG ATC GCT CTA GGT CGC TAG CAA-3 0 .
Clonogenic growth in soft agar pEGFP-N1 (2 mg) vector encoding GFP was transiently cotransfected with 10 mg Staf50/pCDNA3, p21 /WAF1 /pCDNA3 or control plasmid pCDNA3 into 8 Â 10 6 U-937 cells by electroporation, using the BioRad gene-pulser (BioRad) with electrical settings of 280 V and 960 mF. After incubation at 371C for 24 h, the cells were sorted in a FACSAria (Becton Dickenson) for GFP positivity and seeded in 3% soft agar at a density of 2000 cells per 30 mm dish. Colonies (440 cells) were scored after 9 days.
